Sort   by:  
 Page size 
UnknownTen-year projection of white-nose syndrome disease dynamics at the southern leading-edge of infection in North America.
Not available
S-EPMC8170204 | biostudies-literature
UnknownStudy protocol for a multicentre, randomised, double-blinded, placebo-controlled, multi-arm, multi-stage, trial of SpironolacTone and famciclOovir in the treatment of Progressive Multiple Sclerosis to prevent disability progression: the STOP-MS trial.
Not available
S-EPMC12730750 | biostudies-literature
UnknownClinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination.
Not available
S-EPMC5800335 | biostudies-literature
UnknownMRI Patterns Distinguish AQP4 Antibody Positive Neuromyelitis Optica Spectrum Disorder From Multiple Sclerosis.
Not available
S-EPMC8458658 | biostudies-literature
UnknownThe clinical relevance of MOG antibody testing in cerebrospinal fluid.
Not available
S-EPMC11537122 | biostudies-literature
UnknownOral corticosteroid dosage and taper duration at onset in myelin oligodendrocyte glycoprotein antibody-associated disease influences time to first relapse.
Not available
S-EPMC11503134 | biostudies-literature
UnknownExamining the environmental risk factors of progressive-onset and relapsing-onset multiple sclerosis: recruitment challenges, potential bias, and statistical strategies.
Not available
S-EPMC10770262 | biostudies-literature
Sort   by:  
 Page size